The results of PPI network topology analysis showed that the therapeutic effect of this drug on hepatitis was mainly achieved by regulating RELA, AKT1, JUN, MAPK1, TP53, CCND1, MYC, RB1, MAPK14, NFKBIA, CDKN1A, HIF1A, ESR1, and FOS. Here, CDKN1A is linked to hepatitis A virus infection.